利用iRGD构建外泌体用于lncRNA PLBD1-AS1介导的靶向RNAi治疗胰腺癌症
核心信息
- 论文英文标题: Engineering exosomes with iRGD for targeted RNAi therapy against pancreatic cancer mediated by long non-coding RNA PLBD1-AS1
- 期刊: PLoS One
- 发表年份: 2026
- DOI: 10.1371/journal.pone.0345697
- PMID/PMCID: 41950246; PMC13061246
研究概览
This study identifies the long non-coding RNA PLBD1-AS1 as a functional oncogenic lncRNA enriched in PDAC exosomes. Our findings reveal a novel mechanism of exosome-mediated metabolic crosstalk in PDAC and establish a promising RNAi-based therapeutic strategy targeting this lethal malignancy.
核心发现
Tumor-derived exosomes play critical roles in pancreatic ductal adenocarcinoma (PDAC) progression by mediating intercellular communication within the tumor microenvironment.
This study identifies the long non-coding RNA PLBD1-AS1 as a functional oncogenic lncRNA enriched in PDAC exosomes.
We demonstrate that PLBD1-AS1 promotes tumor cell proliferation, migration, and invasion by interacting with the glycolytic enzyme ALDOA and enhancing glycolytic flux.
Furthermore, tumor exosomes deliver PLBD1-AS1 to pancreatic stellate cells (PSC), augmenting their glycolysis and facilitating their activation into cancer-associated fibroblasts, thereby shaping a pro-tumorigenic microenvironment.
Echo Biotech 角色
对MSC EV ExoLoad负载lncRNA-siRNA & ExoBrooch iRGD脂锚
关联平台: Exoomics®, Echosome®, Research Reagents & Tools
关联服务与能力: EV lncRNA/mRNA Sequencing, Small RNA / Cargo Loading, Targeting Peptide / Surface Modification, Research Reagent / Product Supply
关联产品或试剂: ExoLoad® Nucleic Acid Loading Kit, ExoBrooch™ Targeting Peptide/Lipid Anchor Kit
参考文献
原始论文: Engineering exosomes with iRGD for targeted RNAi therapy against pancreatic cancer mediated by long non-coding RNA PLBD1-AS1 PloS one. 2026. DOI: 10.1371/journal.pone.0345697. PMID/PMCID: 41950246; PMC13061246.